| The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015 | 456 | 2015 |
| Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer C Isella, F Brundu, SE Bellomo, F Galimi, E Zanella, R Porporato, C Petti, ... Nature communications 8 (1), 15107, 2017 | 263 | 2017 |
| Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas G Migliardi, F Sassi, D Torti, F Galimi, ER Zanella, M Buscarino, D Ribero, ... Clinical Cancer Research 18 (9), 2515-2525, 2012 | 214 | 2012 |
| IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies ER Zanella, F Galimi, F Sassi, G Migliardi, F Cottino, SM Leto, B Lupo, ... Science translational medicine 7 (272), 272ra12-272ra12, 2015 | 116 | 2015 |
| Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas SM Leto, F Sassi, I Catalano, V Torri, G Migliardi, ER Zanella, M Throsby, ... Clinical Cancer Research 21 (24), 5519-5531, 2015 | 104 | 2015 |
